The data from the trials support a desirable safety profile at dose levels displaying indications of pharmacologic activity. HBI-3000 is being developed as a potential treatment for both atrial and ventricular arrhythmias.
Preclinical data developed by Huya and its Chinese partner, along with the Chinese clinical trial data suggest that HBI-3000 may have safety advantages over other anti-AF agents and exhibits broad spectrum ion channel inhibition without pro-arrhythmic activity that suggests it may also be safer to use in treatment of ventricular arrhythmias.
Company has reported the formation of clinical advisory team for its new anti-arrhythmic compound. The advisory team consists of world-class biomedical researchers who will provide guidance to Huya and its Chinese partner, Shanghai Institute of Materia Medica (SIMM), throughout the course of an innovative US/China co-development process for HBI-3000.